US Patent

US8513223 — Substituted tetracycline compounds for treatment of inflammatory skin disorders

Method of Use · Assigned to Paratek Pharmaceuticals Inc · Expires 2029-12-07 · 4y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods and compositions for treating skin disorders such as acne and rosacea.

USPTO Abstract

Methods and compositions for the treatment of skin disorders (e.g., acne, rosacea) are described.

Drugs covered by this patent

sarecycline-hydrochloride (SARECYCLINE HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2406`	—	sarecycline-hydrochloride
`U-2406`	—	sarecycline-hydrochloride
`U-2406`	—	sarecycline-hydrochloride

Patent Metadata

Patent number: US8513223
Jurisdiction: US
Classification: Method of Use
Expires: 2029-12-07
Drug substance claim: No
Drug product claim: No
Assignee: Paratek Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.